ANGELA HAN: Open Payments
NPI 1629242839 · SAN MARCOS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$360 in 14 payments from 8 companies in 2025. Trend: 2023 $411 · 2024 $449 · 2025 $360
Food & beverage: $360
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $134 |
| Otsuka America Pharmaceutical, Inc. | 3 | $73 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $28 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
| Alkermes, Inc. | 1 | $20 |
| Janssen Pharmaceuticals, Inc | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
Products named: INGREZZA, REXULTI, AUSTEDO XR, CAPLYTA, ABILIFY ASIMTUFII, COBENFY, ARISTADA, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
